Pembrolizumab治療子宮頸癌的檢視

The Role of Pembrolizumab in Management of Cervical Cancer

免疫治療對子宮頸癌的生成、惡化和存活有相當的重要性，並對以前因化療等所產生的免疫抑制，功能恢復正常。Pembrolizumab計劃細胞死亡接受器1（PD-1）的免疫檢查點阻斷劑，乃為人類單株免疫球蛋白G4（IgG4）抗體，它可阻止與T細胞中PD-1與其計劃細胞死亡接受器配體（PD-L1）的結合，使T細胞恢復活性，抑制腫瘤細胞。最近研究證明，以pembrolizumab來治療晚期、復發和持續性的子宮頸癌會有效果。

The immune system plays an active role in the pathogenesis of cervical cancer,as well as the mechanisms of disease progression and overall survival. Immunotherapyin gynecological cancer could help to revert immunosuppression due toprior treatment. Pembrolizumab, a checkpoint inhibitor of programmed-celldeath-receptor 1(PD-1), is a fully humanized monoclonal immunoglobulin G4(IgG4) antibody and it binds to PD-1 on T-cells therby inhibiting interactionswith its ligand, proprammed death ligand-1(PD-L1), which is primarily expressedon tumor cells. As a result, T-cells are activated and can attack cancercells. Pembrolizumab is currently also being studies for use in cervical cancerwith recent studies indicating promising results in advanced, recurrent, or persistentcervical cancer.